![]() |
Market Research Report
Product code
1034309
Chronic Hepatitis B Virus (CHB) - Epidemiology Forecast to 2030 |
Chronic Hepatitis B Virus (CHB) - Epidemiology Forecast to 2030 |
Published: Pre-Order
DelveInsight Business Research LLP
Content info: 100 Pages
Delivery time: 2-10 business days
|
DelveInsight's 'Chronic Hepatitis B Virus (CHB) - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted CHB epidemiology in the 7MM, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Hepatitis B is the most common serious liver infection in the world. It is caused by the hepatitis B virus that attacks and injures the liver. Millions of people are living with a chronic hepatitis B infection all around the world. The hepatitis B virus (HBV) is transmitted through blood and infected bodily fluids. It can be passed to others through direct contact with blood, unprotected sex, and use of illegal drugs, unsterilized or contaminated needles. Children with hepatitis B are more likely to contract it through:
HBV is most commonly spread through sexual contact, accounting for nearly two-thirds of acute HBV cases. It is considered as a "silent epidemic" because most people do not have symptoms when they are newly infected or chronically infected. Thus, they can unknowingly spread the virus to others and continue the silent spread of hepatitis B. Most hepatitis B infections clear up within 1-2 months without treatment. When the infection lasts more than 6 months, it can develop into chronic hepatitis B, which can lead to chronic inflammation of the liver, cirrhosis (scarring of the liver), liver cancer, and/or liver failure. HBV infection has been identified as an important cause of chronic hepatitis (35.9%) and liver cirrhosis (44.2%).
The symptoms of hepatitis B include fatigue, poor appetite, stomach pain, fever, nausea, vomiting, and occasionally joint pain, hives, or rash. Urine may become darker in color, and then jaundice (yellowing of the skin and whites of the eyes) may appear. Adults are more likely than children to develop symptoms; however, up to 50% of adults who have acute infection do not have any symptoms. The symptoms may appear within 6 weeks to 6 months after exposure, but usually 4 months. The virus can be found in blood and other body fluids several weeks before symptoms appear and generally persists for several months afterward.
The Chronic Hepatitis B Virus epidemiology division provides the insights about historical and current Chronic Hepatitis B Virus patient pool and forecasted trend for each seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
In 2020, the overall prevalent cases of CHB accessed to be around 5,858,038 in the 7MM, which are expected to grow during the forecast period, i.e., 2021-2030.
The disease epidemiology covered in the report provides historical as well as forecasted Chronic Hepatitis B Virus epidemiology segmented as [Total Prevalent cases of CHB, Total Diagnosed Prevalent cases of CHB, Gender-Specific Cases of CHB, Age-Specific Cases of CHB, CHB cases by Impact on Liver (i.e., decompensated and compensated), and Total treated cases of CHB] in the 7MM, covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), and Japan from 2017 to 2030.
Among the 7MM, the United States accounted for nearly 40% of the total prevalent population of CHB in the year 2020.
In EU-5 countries the highest number of diagnosed cases of CHB were in Germany, followed by Italy.
As per the secondary findings, overall CHB Virus affects more males than females. In addition, around half of the CHB cases are reported in the people age group of 44 years and below. In the 7MM, the age-specific diagnosed prevalent cases of CHB were 60,561, 519,638, 479,929, 510,925, 366,771, and 93,968 cases for the age group less than 18 years, 18-34 years, 35-44 years, 45-54 years, 55-64 years, and ≥65 years, in 2020.
We interview, KOL's and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the over CHB scenario of the indications.
The CHB Epidemiology report will allow the user to -
Develop business strategies by understanding the trends shaping and driving the global CHB market
Study Period: 2017-2030